Gadobenate dimeglumine (BOPTA) enhanced MR imaging: Patterns of enhancement in normal liver and cirrhosis

To determine whether gadobenate dimeglumine (BOPTA) will adequately enhance cirrhotic liver parenchyma, and to document the enhancement patterns in cirrhosis, 14 cirrhotic and 20 non‐cirrhotic patients were evaluated before and 60–120 minutes after gadolinium‐BOPTA. Proof of liver cirrhosis was biopsy (6), surgical resection (3), and clinical follow‐up (5). Enhancement effects were compared quantitatively by determining the liver signal‐to‐noise ratio (SNR) and signal enhancement in both populations. Qualitatively assessment of the liver enhancement was performed and classified as homogeneous or heterogeneous. Quantitative analysis: cirrhotic liver parenchyma presented a higher increase in SNR values, relative to noncirrhotic liver parenchyma, on postcontrast images. Likewise the signal enhancement of cirrhotic liver parenchyma was superior to non‐cirrhotic liver on T1‐weighted SE images (P = .02) and in‐phase GRE images (P < .001). There was no statistical difference on out‐of‐phase GRE images. Qualitative analysis: on T1‐weighted SE postcontrast images, cirrhotic liver parenchyma showed a homogeneous enhancement in 7 patients and heterogeneous in 7. Whereas on GRE images, cirrhotic parenchyma showed heterogeneous enhancement in 9 patients and homogeneous in 5 patients. The heterogeneous enhancement was due to the presence of hypointense nodules in 7 patients and hyperintense nodules in 2 patients. In conclusion, our study has shown that the hepatobiliary contrast agent Gd‐BOPTA is effective in the cirrhotic liver, demonstrating an increased liver enhancement compared with non‐cirrhotic patients.

[1]  A. Spinazzi,et al.  Interim results of phase II clinical testing of gadobenate dimeglumine. , 1994, Investigative radiology.

[2]  G. Vittadini,et al.  Preclinical profile of Gd-BOPTA. A liver-specific MRI contrast agent. , 1990, Investigative radiology.

[3]  R. Bryan,et al.  MR imaging of susceptibility-induced magnetic field inhomogeneities. , 1988, Radiology.

[4]  R. Passariello,et al.  Comparison of Gd-BOPTA with Gd-DTPA in MR imaging of rat liver. , 1990, Radiology.

[5]  C. de Haën,et al.  Soluble‐type hepatobiliary contrast agents for MR imaging , 1993, Journal of magnetic resonance imaging : JMRI.

[6]  G. Dodd,et al.  Detection of malignant tumors in end-stage cirrhotic livers: efficacy of sonography as a screening technique. , 1992, AJR. American journal of roentgenology.

[7]  O. Matsui,et al.  Hepatocellular carcinoma: correlation of MR imaging and histopathologic findings. , 1992, Radiology.

[8]  G. Morana,et al.  Focal malignant hepatic lesions: MR imaging enhanced with gadolinium benzyloxypropionictetra-acetate (BOPTA)--preliminary results of phase II clinical application. , 1996, Radiology.

[9]  E M Haacke,et al.  Reduction of T2* dephasing in gradient field-echo imaging. , 1989, Radiology.

[10]  K. Ohtomo,et al.  Confluent hepatic fibrosis in advanced cirrhosis: evaluation with MR imaging. , 1993, Radiology.

[11]  F. Cavagna,et al.  Evaluation of the hepatocyte‐specific contrast agent gadobenate dimeglumine for MR imaging of acute hepatitis in a rat model , 1997, Journal of magnetic resonance imaging : JMRI.

[12]  T. Murakami,et al.  Cirrhosis of the liver: MR imaging with mangafodipir trisodium (Mn-DPDP). , 1996, Radiology.

[13]  C. McMahon,et al.  Gadobenate dimeglumine--a new contrast agent for MR imaging: preliminary evaluation in healthy volunteers. , 1992, AJR. American journal of roentgenology.

[14]  M. Bernardino,et al.  Hepatocellular tumors: characterization with Mn-DPDP-enhanced MR imaging. , 1993, Radiology.

[15]  O. Matsui,et al.  Delayed enhancement of fibrotic areas in hepatic masses: CT-pathologic correlation. , 1992, Journal of computer assisted tomography.

[16]  G. Dodd,et al.  Malignancies in patients with cirrhosis: CT sensitivity and specificity in 200 consecutive transplant patients. , 1994, Radiology.

[17]  H. Popper.  Pathologic aspects of cirrhosis. A review. , 1977, The American journal of pathology.